Brazil's Viveo closes $160M share sale to tame its debt load
What's the deal? Brazilian medical distributor ViveoDealroom has a profile for this one. Try Dealroom → has completed a post-IPO equity raise of US$221.8M, subscribing 99.71% of the operation's US$222.5M ceiling. Roughly 963 million new ordinary shares were taken up at US$0.23 each; some 2.8 million unsubscribed shares will not be issued.
Why now? The raise continues a debt renegotiation Viveo closed in June that pushed maturities out to 2034 and cut payments due in 2026–2028 by 77%.
What's the endgame? The capital increase is designed to reduce leverage. The bulk of it came from a US$161.2M subscription during the preference period, with a further US$59M in additional requests and US$1.61M subscribed in the leftover-shares window.
Banco BTG PactualDealroom has a profile for this one. Try Dealroom → committed to subscribe leftover shares — capitalising credits from Viveo debentures — up to a 19.9% stake, a move conditioned on unrestricted approval from Brazil's antitrust regulator, CADE.
What could go wrong? Raising nearly the full target does not fix profitability. In the second quarter, net leverage stood at 3.73 times, and Viveo reported an adjusted loss and revenue below expectations, despite improved margins.
The signal: The near-complete raise ranks around the 90th percentile among all-time post-IPO equity rounds for health companies in Brazil, underscoring how far the sector will go to deleverage under financial pressure — even as the harder task of returning to profit remains.
Read more: valor.globo.com
Image credit: Generated with Gemini
